Racial Disparities in Comorbidity Patterns of Early-Onset Liver Cancer: A Machine Learning Analysis
Cancer Control · 2025
DOI: 10.1177/10732748251363687 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Control, 2025. Verfasst von Bingya Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, University of California Irvine, Irvine, CA, USA. Hauptthemen laut MEDLINE: Machine Learning, Liver Neoplasms, Health Status Disparities. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, UCI Presidential Funding of Dr Oladele Ogunseitan.
Abstract (Originalsprache)
Introduction
The incidence of early-onset liver cancer (EOLC) has been increasing in many countries, yet evidence on its etiology remains limited, particularly outside the Asian population. This case-control study explores the comorbidity patterns of EOLC and develops race/ethnicity-specific machine learning (ML) models to predict liver cancer risk.
Methods
We included patients diagnosed with primary liver cancer between ages 18 and 49 from the University of California Health Data Warehouse, matching each patient with five controls. ML classification methods, including decision trees, random forests, logistic regression, XGBoost, and LightGBM, were used to assess liver cancer risk based on demographics and comorbidities. Model performance was evaluated using F1 scores, and SHapley Additive exPlanations (SHAP) was applied to identify the most influential comorbidities within each racial group.
Results
A total of 1574 patients and 7870 controls were identified. Asian and Pacific Islanders (API) had significantly higher rates of Hepatitis B virus (HBV) infection, while Hispanics had higher prevalences of cirrhosis, hypertension, diabetes, and Hepatitis C virus (HCV) infection. Whites showed higher rates of anxiety, asthma, hypothyroidism, and cholangitis. Race/ethnicity-specific models for API (F1 score = 0.77, AUC = 0.90) and Hispanics (F1 score = 0.77, AUC = 0.92) outperformed the model for Whites (F1 score = 0.64, AUC = 0.87) in the validation dataset. The SHAP results indicated that HBV infection was the dominant comorbidity for API, and HCV and metabolic disorders were notable among Hispanics. In contrast, the White population showed a broader and less concentrated comorbidity pattern.
Conclusions
Our study highlights significant racial disparities in comorbidity patterns for early-onset liver cancer, demonstrating the potential of ML models to identify high-risk populations and inform targeted prevention strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, University of California Irvine, Irvine, CA, USA.
- Department of Informatics, Donald Bren School of Information and Computer Science, University of California Irvine, Irvine, CA, USA.
- Department of Emergency Medicine, School of Medicine, University of California Irvine, Irvine, CA, USA.
- Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Orange, CA, USA.
- Department of Population Health and Disease Prevention, University of California Irvine, Irvine, CA, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
- UCI Presidential Funding of Dr Oladele Ogunseitan
Zitieren
APA
Ma, B., Zheng, K., Lee, F. C., & Lu, Y. (2025). Racial Disparities in Comorbidity Patterns of Early-Onset Liver Cancer: A Machine Learning Analysis. Cancer Control. https://doi.org/10.1177/10732748251363687
Vancouver
Ma B, Zheng K, Lee FC, Lu Y. Racial Disparities in Comorbidity Patterns of Early-Onset Liver Cancer: A Machine Learning Analysis. Cancer Control. 2025. doi:10.1177/10732748251363687
BibTeX
@article{Ma2025,
author = {Ma, Bingya and Zheng, Kai and Lee, Fa-Chyi and Lu, Yunxia},
title = {Racial Disparities in Comorbidity Patterns of Early-Onset Liver Cancer: A Machine Learning Analysis},
journal = {Cancer Control},
year = {2025},
doi = {10.1177/10732748251363687}
}
EUVIMED